Phosphatidylserine gets marketed broadly as a "brain booster," but the actual trial evidence is narrower and more specific than that phrase suggests — which, in this case, is a point in its favor rather than against it. The trials that hold up are almost all run in the same population: older adults already showing signs of cognitive decline, tested for months at a time, on a fairly specific dose range. That's a much more useful thing to know than "supports brain health."
What the trial evidence actually covers
A systematic review and meta-analysis pooled nine studies — five randomized controlled trials and four pre-post studies, 961 participants total — testing phosphatidylserine doses of 100-300mg/day over periods ranging from 6 weeks to 6 months.1 The population wasn't healthy young adults looking for an edge; it was older adults already experiencing cognitive decline. Within that population, the analysis found a real positive effect specifically on memory, with no significant adverse effects reported across the pooled studies.
Memory specifically, not "cognition" broadly
This is the detail most marketing drops: the benefit clustered on memory, not on a broad basket of cognitive domains. That's a more specific and more credible claim than "supports brain function" — it also means the evidence doesn't clearly support using phosphatidylserine as a general nootropic for a healthy adult with no cognitive complaints, since that's not the population or outcome the trials were built around.
The source question: soy, sunflower, and a discontinued original
Here's a wrinkle that most product pages skip entirely. The earliest and largest body of phosphatidylserine research — including much of what fed into the meta-analysis above — used PS extracted from bovine (cow) brain cortex. That ingredient largely disappeared from the market after the 1990s, when concerns about bovine spongiform encephalopathy (BSE, "mad cow disease") prion contamination made animal-brain-derived ingredients a hard sell to regulators and manufacturers alike.2 What replaced it is plant-derived PS, made by chemically converting the phospholipids in soy or sunflower lecithin into phosphatidylserine — the two forms sold almost universally today.
Soy- and sunflower-derived PS are not identical to each other, and neither is identical to the original bovine version. Bovine cortex PS carried a fatty acid profile including some DHA; soy-derived PS is built mostly on linoleic acid (around 62%) with some oleic acid; sunflower-derived PS runs even higher in linoleic acid (around 70%) and slightly higher in oleic acid than soy.2 Sunflower PS also carries a practical advantage for people avoiding soy or its associated allergens, which is part of why the FDA has issued a string of "no questions" GRAS (Generally Recognized As Safe) determinations covering PS from multiple sources, most recently a 2019 sunflower-derived PS notice permitting use at levels up to 300mg per serving in medical foods.2 The same FDA filing cites human trials establishing safety at daily doses up to 300mg for as long as 6 months — consistent with the dose range in the memory meta-analysis above.
| Source | Status today | Notes |
|---|---|---|
| Bovine cortex PS | Effectively discontinued | Original research substrate; withdrawn over BSE prion-contamination concerns2 |
| Soy-derived PS | Widely sold, FDA GRAS | ~62% linoleic acid; most common form in current products2 |
| Sunflower-derived PS | Newer, FDA GRAS (2019) | ~70% linoleic acid; soy-free alternative, approved up to 300mg/serving in medical foods2 |
None of this means soy or sunflower PS "doesn't work" — the FDA's safety review and the dose levels it approved track closely with what the clinical trials actually used. But it's a real distinction worth knowing if you're comparing labels: "phosphatidylserine" alone doesn't tell you which plant it came from, and the bovine-derived form that generated some of the earliest headlines isn't what's in a bottle today.
A longer, newer trial in the exact population that matters
Most of the classic phosphatidylserine trials ran for a few months at most. A 2024 randomized, double-blind, placebo-controlled trial extended that window considerably: 190 Chinese older adults (mean age just under 68) with diagnosed mild cognitive impairment took a food supplement containing phosphatidylserine — two capsules daily, 31.5mg PS per capsule — for a full 12 months.3 That's a notably lower daily PS dose than the 100-300mg range used in most earlier trials, run over a much longer period.
At 12 months, the supplement group showed statistically significant improvements over placebo on arithmetic testing, similarity/abstraction testing, and short-term memory. The trial also measured blood biomarkers and found increases in alpha-linolenic acid (ALA), DHA, and acetylcholine in the supplement group — and calculated that the rise in ALA alone statistically accounted for roughly 20% of the short-term memory improvement.3 That's a genuinely useful addition to the evidence base: it's a longer trial than most, run in the specific population — diagnosed MCI, not just "older adults" — where PS's effect has looked clearest, and it starts to sketch a mechanism rather than just reporting a test-score change.
Phosphatidylserine's evidence is real, replicated, and specific — a legitimate memory-focused option for older adults with diagnosed decline, not an all-purpose brain enhancer.
Where it sits relative to what we already sell
This lands in similar territory to Bacopa monnieri in our range evaluations — a real, specific, replicated effect on memory in a defined population, rather than the broad "focus and clarity" framing most brain-health marketing leans on. Bacopa's effect takes 6-12 weeks of continuous use to show up and centers on processing speed and working memory in a broader adult population; phosphatidylserine's effect centers more tightly on memory itself, in a population that's already showing decline, and the newer 12-month trial suggests the benefit may build with sustained, even lower-dose, use rather than requiring the full 300mg ceiling from day one.
What this means if you're actually evaluating it
The practical upshot is narrower than most marketing copy: the evidence supports phosphatidylserine as a memory-focused option for older adults who are already noticing decline — not as a general-purpose cognitive enhancer for a healthy 30-year-old who wants an edge before a big presentation. The dose range with the most trial support sits at 100-300mg/day, typically split across two or three servings, sustained for at least six weeks and more likely three months or longer before judging results. The newer 12-month trial suggests a lower daily dose, taken consistently for a full year, can also move the needle — which points toward consistency mattering as much as, or more than, hitting the top of the dose range.13 None of the trials behind this evidence tested phosphatidylserine as a short-term or as-needed aid, so that's not a use case the data can speak to either way.
Bottom line
Phosphatidylserine has genuine trial support for improving memory specifically in older adults already showing cognitive decline, now reinforced by a longer, more recent trial in adults with diagnosed mild cognitive impairment. It's a real, if narrow, positive result — not the all-purpose brain enhancer it's often sold as, but a legitimate, evidence-backed option for the specific population and outcome the trials actually tested. Worth knowing, too: the soy- or sunflower-derived PS in today's supplements isn't identical to the bovine cortex form used in some of the original research, though the dose levels and safety data line up closely enough that this is a labeling detail to understand, not a reason for concern.
Phosphatidylserine is in Cognitive Support — sunflower-derived, matching the sourcing discussed above — but without an individually disclosed dose yet. That's part of the same ingredient-disclosure work underway for Cognitive Support, which starts with GABA and will extend to other ingredients — including Bacopa and phosphatidylserine — over time; we'll add the actual dose once that data is confirmed.
This article is for informational purposes only and has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. Speak with a healthcare provider before starting any new supplement, especially if you take medication or have an existing health condition.
References
- Effect of phosphatidylserine on cognitive function in the elderly: A systematic review and meta-analysis. Korean Journal of Food Science and Technology, 2022. koreascience.kr
- "Phosphatidylserine Derived from Sunflower Lecithin." GRAS Notice No. GRN 000636, U.S. Food and Drug Administration, 2019. fda.gov
- "Effects of a food supplement containing phosphatidylserine on cognitive function in Chinese older adults with mild cognitive impairment: A randomized double-blind, placebo-controlled trial." Journal of Affective Disorders, 2024. pubmed.ncbi.nlm.nih.gov
Related reading: Bacopa Monnieri: The Evidence Is Real, But It Takes Weeks — Not Days and Creatine and the Brain.
Want to know the moment the exact phosphatidylserine dose lands on Cognitive Support's label? Join the list — no spam, just the range and the evidence behind it.